Age, Biography and Wiki
William Kaelin Jr. was born on 23 November, 1957 in New York City, New York, U.S., is an American Nobel Laureate, Professor of Medicine at Harvard University. Discover William Kaelin Jr.'s Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 66 years old?
| Popular As |
N/A |
| Occupation |
N/A |
| Age |
66 years old |
| Zodiac Sign |
Sagittarius |
| Born |
23 November 1957 |
| Birthday |
23 November |
| Birthplace |
New York City, New York, U.S. |
| Nationality |
United States
|
We recommend you to check the complete list of Famous People born on 23 November.
He is a member of famous Professor with the age 66 years old group.
William Kaelin Jr. Height, Weight & Measurements
At 66 years old, William Kaelin Jr. height not available right now. We will update William Kaelin Jr.'s Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Who Is William Kaelin Jr.'s Wife?
His wife is Carolyn Scerbo
| Family |
| Parents |
Not Available |
| Wife |
Carolyn Scerbo |
| Sibling |
Not Available |
| Children |
Not Available |
William Kaelin Jr. Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is William Kaelin Jr. worth at the age of 66 years old? William Kaelin Jr.’s income source is mostly from being a successful Professor. He is from United States. We have estimated William Kaelin Jr.'s net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
Professor |
William Kaelin Jr. Social Network
Timeline
William G. Kaelin Jr. (born November 23, 1957) is an American Nobel laureate physician-scientist.
He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute.
His laboratory studies tumor suppressor proteins.
Kaelin was born in New York City on November 23, 1957.
Kaelin earned his bachelor's degree in mathematics and chemistry at Duke University, and stayed to attain an MD, graduating in 1982.
He did his residency in internal medicine at Johns Hopkins School of Medicine and his fellowship in oncology at Dana–Farber Cancer Institute (DFCI).
After deciding as an undergraduate that research was not a strength of his, at DFCI he did research in the lab of David Livingston, where he found success in the study of retinoblastoma.
He was married to breast cancer surgeon Carolyn Kaelin from 1988 until her death from glioblastoma in 2015.
• NIH Physician-Scientist Award (1990)
In 1992, he set up his own lab at DFCI down the hall from Livingston's where he investigated hereditary forms of cancer such as von Hippel–Lindau disease.
Following his post-doctorate, Kaelin set up a laboratory at Dana-Farber in 1993 to continue his research on tumor suppression.
He had become interested in Von Hippel–Lindau disease (VHL).
VHL tumors, caused by gene mutation, were known to be angiogenic, creating blood vessels that secreted erythropoietin (EPO), a hormone known to be part of the body's mechanic to react to hypoxia, or low oxygen levels in the blood.
Kaelin hypothesized that there may be a connection between the formation of VHL tumors and the deficiency of the body to detect oxygen.
Kaelin's research found that in VHL subjects, there are genes that express the formation of a protein critical in the EPO process, but which the mutation suppressed.
Kaelin's work aligned with that of Peter J. Ratcliffe and Gregg Semenza who separately had identified a two-part protein, hypoxia-inducible factors (HIF) that was essential to EPO production and which was triggered by oxygen levels in the blood.
Kaelin's work found that the VHL protein would help regulate the HIF, and in subjects where the VHL proteins were not present, the HIF would overproduce EPO and lead to cancer.
The combined work of Kaelin, Ratcliffe, and Semenza identified the pathway of how cells detect and react to oxygen levels in the blood, and have led to the development of drugs to help patients with anaemia and kidney failure.
He became a professor at Harvard Medical School in 2002.
• Richard and Hinda Rosenthal Foundation Award, AACR (2006)
• Doris Duke Distinguished Clinical Investigator Award (2006)
• Duke University School of Medicine Distinguished Alumni Award (2007)
• Elected member of the Institute of Medicine (2007)
He became assistant director of Basic Science at the Dana–Farber/Harvard Cancer Center in 2008.
His research at Dana–Farber has focused on understanding the role of mutations in tumor suppressor genes in cancer development.
His major work has been on the retinoblastoma, von Hippel–Lindau, and p53 tumor suppressor genes.
His work has been funded by the National Institutes of Health, American Cancer Society, Doris Duke Charitable Foundation and others.
He serves as vice-chair of Scientific Programs on the Damon Runyon Cancer Research Foundation Board of Directors and Chair of the Damon Runyon Physician-Scientist Training Award selection committee and is a member of the board of directors at Eli Lilly and the Stand Up to Cancer scientific advisory committee.
• Canada Gairdner International Award (2010)
• Elected member of the National Academy of Sciences (2010)
• Stanley J. Korsmeyer Award (2012)
• The Scientific Grand Prize of the Lefoulon-Delalande Foundation (2012)
• Steven C. Beering Award (2014)
• Wiley Prize in Biomedical Sciences (2014)
• Elected fellow of the AACR Academy (2014)
In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award.
• Science of Oncology Award, ASCO (2016)
• Princess Takamatsu Award, AACR (2016)
He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.
